The U.S. Patent and Trademark Office (PTO) has allowed two applications submitted byAffinity Biotech Inc. covering a new form of ibuprofen.
Ibuprofen is currently marketed as an over-the-counter analgesic and anti-inflammatorydrug (under trade names such as Motrin, Advil and Nuprin). Affinity Biotech claims thatits form of the drug does not have a burning taste and is potentially less irritating tothe gastrointestinal tract. The patents to be issued to Affinity of Aston, Pa., coverneomorphic ibuprofen compositions and methods for their preparation. Affinity(NASDAQ:AFBI) has additional patent filings relating to the administration of theneomorphic ibuprofen compositions.